The test kit detects SARS-CoV-2 from direct nasal swabs using the ANP NIDS Swab Buffer. Credit: Elchinator / Pixabay.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for ANP Technologies’ NIDS COVID-19 Antigen Rapid Test Kit.

The test is a lateral flow immunoassay (LFA) that is developed using ANP’s Nano-Intelligent Detection System (NIDS) platform technology for the detection of SARS-CoV-2 from direct nasal swabs using NIDS Swab Buffer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It uses highly sensitive antibodies for the detection of the SARS-CoV-2 nucleocapsid protein in nasal swab specimens.

ANP chief technology officer and president Ray Yin said: “The NIDS COVID-19 Antigen Rapid Test was developed using our NIDS technology platform that was initially developed for the rapid detection of various biological warfare agents for the US military more than a decade ago.

“With the Covid-19 pandemic, ANP quickly configured its NIDS platform for the detection of SARS-CoV-2 antigen and achieved outstanding performance under the funding from the Department of Defense and the RADx initiative.”

The NIDS COVID-19 Antigen Rapid Test Kit provides a visual result in 15 minutes based on the presence or absence of pink/purple-coloured lines.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company stated that the test is also effective in the detection of many other Covid-19 variants, including Delta.

ANP business development and contracts senior director Greg Whitham said: “With this pivotal FDA authorisation, ANP is now focusing on the large-scale production of the test kits and welcomes all partnerships and collaborations to improve testing production capacity and speed to market, which is paramount to get folks back to work/school and reopen the economy.”

The NIDS test is authorised for use at the point of care and does not differentiate between SARS-CoV and SARS-CoV-2.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact